vs
阿普塔集团（ATR）与FIVE BELOW, INC（FIVE）财务数据对比。点击上方公司名可切换其他公司
FIVE BELOW, INC的季度营收约是阿普塔集团的1.1倍（$1.0B vs $962.7M），阿普塔集团净利率更高（7.7% vs 3.5%，领先4.2%），FIVE BELOW, INC同比增速更快（23.1% vs 13.5%），阿普塔集团自由现金流更多（$96.9M vs $-133.2M），过去两年阿普塔集团的营收复合增速更高（2.6% vs -11.9%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
Five Below是美国特色折扣礼品连锁品牌，2002年成立，总部位于宾夕法尼亚州费城，主要面向青少年消费群体，旗下绝大多数商品定价不超过5美元，另有少量精选商品最高定价40美元，目前在全美拥有超过1850家线下门店。
ATR vs FIVE — 直观对比
营收规模更大
FIVE
是对方的1.1倍
$962.7M
营收增速更快
FIVE
高出9.5%
13.5%
净利率更高
ATR
高出4.2%
3.5%
自由现金流更多
ATR
多$230.0M
$-133.2M
两年增速更快
ATR
近两年复合增速
-11.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $1.0B |
| 净利润 | $74.3M | $36.5M |
| 毛利率 | — | 33.8% |
| 营业利润率 | 11.0% | 4.2% |
| 净利率 | 7.7% | 3.5% |
| 营收同比 | 13.5% | 23.1% |
| 净利润同比 | -26.4% | 2063.9% |
| 每股收益（稀释后） | $1.13 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRFIVE
| Q4 25 | $962.7M | $1.0B | ||
| Q3 25 | $961.1M | $1.0B | ||
| Q2 25 | $966.0M | $970.5M | ||
| Q1 25 | $887.3M | $1.4B | ||
| Q4 24 | $848.1M | $843.7M | ||
| Q3 24 | $909.3M | $830.1M | ||
| Q2 24 | $910.1M | $811.9M | ||
| Q1 24 | $915.4M | $1.3B |
净利润ATRFIVE
| Q4 25 | $74.3M | $36.5M | ||
| Q3 25 | $127.9M | $42.8M | ||
| Q2 25 | $111.7M | $41.1M | ||
| Q1 25 | $78.8M | $187.5M | ||
| Q4 24 | $100.9M | $1.7M | ||
| Q3 24 | $100.0M | $33.0M | ||
| Q2 24 | $90.5M | $31.5M | ||
| Q1 24 | $83.1M | $202.2M |
毛利率ATRFIVE
| Q4 25 | — | 33.8% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 40.2% | ||
| Q4 24 | — | 30.6% | ||
| Q3 24 | — | 32.7% | ||
| Q2 24 | — | 32.5% | ||
| Q1 24 | — | 41.2% |
营业利润率ATRFIVE
| Q4 25 | 11.0% | 4.2% | ||
| Q3 25 | 14.2% | 5.1% | ||
| Q2 25 | 14.9% | 5.2% | ||
| Q1 25 | 12.8% | 17.7% | ||
| Q4 24 | 14.2% | -0.1% | ||
| Q3 24 | 15.2% | 5.0% | ||
| Q2 24 | 13.8% | 4.5% | ||
| Q1 24 | 12.2% | 20.1% |
净利率ATRFIVE
| Q4 25 | 7.7% | 3.5% | ||
| Q3 25 | 13.3% | 4.2% | ||
| Q2 25 | 11.6% | 4.2% | ||
| Q1 25 | 8.9% | 13.5% | ||
| Q4 24 | 11.9% | 0.2% | ||
| Q3 24 | 11.0% | 4.0% | ||
| Q2 24 | 9.9% | 3.9% | ||
| Q1 24 | 9.1% | 15.1% |
每股收益（稀释后）ATRFIVE
| Q4 25 | $1.13 | $0.66 | ||
| Q3 25 | $1.92 | $0.77 | ||
| Q2 25 | $1.67 | $0.75 | ||
| Q1 25 | $1.17 | $3.40 | ||
| Q4 24 | $1.48 | $0.03 | ||
| Q3 24 | $1.48 | $0.60 | ||
| Q2 24 | $1.34 | $0.57 | ||
| Q1 24 | $1.23 | $3.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $524.5M |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $2.7B | $2.0B |
| 总资产 | $5.3B | $4.8B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资ATRFIVE
| Q4 25 | $409.5M | $524.5M | ||
| Q3 25 | $264.8M | $670.2M | ||
| Q2 25 | $169.8M | $624.0M | ||
| Q1 25 | $136.8M | $528.8M | ||
| Q4 24 | $226.2M | $216.6M | ||
| Q3 24 | $327.9M | $327.7M | ||
| Q2 24 | $223.9M | $369.6M | ||
| Q1 24 | $201.1M | $460.1M |
总债务ATRFIVE
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
股东权益ATRFIVE
| Q4 25 | $2.7B | $2.0B | ||
| Q3 25 | $2.8B | $1.9B | ||
| Q2 25 | $2.7B | $1.9B | ||
| Q1 25 | $2.5B | $1.8B | ||
| Q4 24 | $2.5B | $1.6B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.4B | $1.6B | ||
| Q1 24 | $2.3B | $1.6B |
总资产ATRFIVE
| Q4 25 | $5.3B | $4.8B | ||
| Q3 25 | $5.1B | $4.6B | ||
| Q2 25 | $4.9B | $4.5B | ||
| Q1 25 | $4.5B | $4.3B | ||
| Q4 24 | $4.4B | $4.2B | ||
| Q3 24 | $4.6B | $4.0B | ||
| Q2 24 | $4.5B | $3.9B | ||
| Q1 24 | $4.4B | $3.9B |
负债/权益比ATRFIVE
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $-80.1M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $-133.2M |
| 自由现金流率自由现金流/营收 | 10.1% | -12.8% |
| 资本支出强度资本支出/营收 | 9.0% | 5.1% |
| 现金转化率经营现金流/净利润 | 2.47× | -2.19× |
| 过去12个月自由现金流最近4个季度 | $299.6M | $323.0M |
8季度趋势，按日历期对齐
经营现金流ATRFIVE
| Q4 25 | $183.7M | $-80.1M | ||
| Q3 25 | $177.6M | $93.0M | ||
| Q2 25 | $126.0M | $132.7M | ||
| Q1 25 | $82.7M | $363.5M | ||
| Q4 24 | $178.2M | $-30.6M | ||
| Q3 24 | $229.3M | $71.3M | ||
| Q2 24 | $143.6M | $26.4M | ||
| Q1 24 | $92.3M | $407.7M |
自由现金流ATRFIVE
| Q4 25 | $96.9M | $-133.2M | ||
| Q3 25 | $114.3M | $48.3M | ||
| Q2 25 | $62.5M | $96.5M | ||
| Q1 25 | $25.9M | $311.4M | ||
| Q4 24 | $112.2M | $-111.0M | ||
| Q3 24 | $162.7M | $-32.4M | ||
| Q2 24 | $75.4M | $-61.4M | ||
| Q1 24 | $16.7M | $304.6M |
自由现金流率ATRFIVE
| Q4 25 | 10.1% | -12.8% | ||
| Q3 25 | 11.9% | 4.7% | ||
| Q2 25 | 6.5% | 9.9% | ||
| Q1 25 | 2.9% | 22.4% | ||
| Q4 24 | 13.2% | -13.2% | ||
| Q3 24 | 17.9% | -3.9% | ||
| Q2 24 | 8.3% | -7.6% | ||
| Q1 24 | 1.8% | 22.8% |
资本支出强度ATRFIVE
| Q4 25 | 9.0% | 5.1% | ||
| Q3 25 | 6.6% | 4.4% | ||
| Q2 25 | 6.6% | 3.7% | ||
| Q1 25 | 6.4% | 3.7% | ||
| Q4 24 | 7.8% | 9.5% | ||
| Q3 24 | 7.3% | 12.5% | ||
| Q2 24 | 7.5% | 10.8% | ||
| Q1 24 | 8.3% | 7.7% |
现金转化率ATRFIVE
| Q4 25 | 2.47× | -2.19× | ||
| Q3 25 | 1.39× | 2.17× | ||
| Q2 25 | 1.13× | 3.22× | ||
| Q1 25 | 1.05× | 1.94× | ||
| Q4 24 | 1.77× | -18.13× | ||
| Q3 24 | 2.29× | 2.16× | ||
| Q2 24 | 1.59× | 0.84× | ||
| Q1 24 | 1.11× | 2.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
FIVE
暂无分部数据
